Table 1.
Clinical trials of anti-BCMA CAR-T cells for MM
| Institution | NCI | Upenn | Bluebird Multi-Inst (Bb2121) | Nanjing Legend (LCAR-B38M) | MSK |
| Scfv derived from | Murine hybridoma | Human library | Murine hybridoma | Murine hybridoma | Human library |
| Co-stimulatory domain | CD28 | 4-1BB | 4-1BB | 4-1BB | 4-1BB |
| Gene transfer | Retrovirus | Lentivirus | Lentivirus | Lentivirus | Retrovirus |
| Conditioning | Cy + Flu | Cohort 1: none Cohorts 2 and 3: Cy |
Cy + Flu | Cy | Cy + Flu |
| BCMA Ag required | > 50% | No requirement | > 50% | “Clear expression” | > 1% |
| ClinicalTrials.gov identifier/reference | NCT022159679,10 | NCT0254616727 | NCT0265892928 | NCT0309065929 | NCT03070327 |
| Median prior lines | 7 | 9 | 7 | 3 | Not yet reported |
| Accrual | Completed (26 patients) | Completed (24 patients, data reported) | Ongoing (21 patients, data reported) | Ongoing (19 patients, data reported) | Not yet reported |
| Response | 13 Of 16 (81%) ORR at highest dose | 6 Of 10 (60%) ORR at high dose with Cy conditioning | 17 Of 18 (94%) ORR at higher doses | 19 Of 19 (100%) ORR | Not yet reported |
| Elimination gene | No | No | No | No | Truncated EGFR |
NCI National Cancer Institute, UPenn University of Pennsylvania, MSK Memorial Sloan Kettering, scFv single chain variable fragment, Cy + Flu cyclophosphamide+ fludarabine